Treatment
Cell clinical trials
We’re tracking 5,682 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT05472649Enrolling by invitation
Long-term follow-up after gene-modified cell therapy
This study checks your health over time after you previously received gene-modified cell therapy in a Sorrento-sponsored trial. It helps researchers understand long-term safety and outcomes and may lead to better care for future patients.
Philadelphia, PennsylvaniaAges Any age - NCT04762459Enrolling by invitationPhase 3
Almonertinib after lung tumor surgery, with or without chemo
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Beijing, Beijing MunicipalityAges 18–130 - NCT04650568Enrolling by invitation
Stem cell treatment after ACL ligament surgery
This trial studies whether adding mesenchymal stem cells during ACL (knee ligament) reconstruction helps the knee heal better. You might be eligible if your ACL injury is recent and you’re having a specific type of graft surgery.
Chicago, IllinoisAges 18–60 - NCT04628585Enrolling by invitation
Follow-up for people with sickle cell treated with gene therapy
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
Birmingham, AlabamaAges 2–53 - NCT04503213Enrolling by invitation
Testing CSF1R brain disease after stem cell transplant
This study looks at how CSF1R-related leukoencephalopathy (a genetic brain condition) behaves after a stem cell transplant. It may help doctors understand expected brain and walking changes after treatment.
Jacksonville, FloridaAges 18 years+ - NCT04210791Enrolling by invitation
Stem cell transplant using your own cells for AL amyloidosis
This trial tests whether an autologous stem cell transplant (using your own stem cells) can help people with newly diagnosed AL amyloidosis. It may be offered to help your body reset abnormal disease-producing cells, based on your health and test results.
Nanjing, JiangsuAges 18–75 - NCT04208529Enrolling by invitationPhase 3
Long-term follow-up after receiving CTX001 infusion
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
Palo Alto, CaliforniaAges 2 years+ - NCT04178915Enrolling by invitation
Blood marker study to predict severe bacterial lung infection
This study looks at specific immune cells and how fats are transported in the blood to predict which people will have a severe bacterial infection (like pneumonia or sepsis). Your results may help doctors identify higher-risk patients earlier.
MinskAges 18–60 - NCT07491497RecruitingPhase 1/Phase 2
TRI-611 for ALK-positive lung cancer
This study tests an experimental pill for people with a specific type of lung cancer. The trial will see if the drug is safe and if it helps shrink tumors.
San Francisco, CaliforniaAges 18 years+ - NCT07801430Recruiting
Extra lymph node removal in left lung cancer surgery
This trial compares two ways of doing lung cancer surgery for early-stage tumors in the left lung. Some participants will have more lymph nodes removed (station 4L) and others will not, to see if the extra removal helps prevent the cancer from coming back.
Shanghai, XuhuiAges 18–75 - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT07089199RecruitingPhase 2
Drug combo before surgery for stage III lung cancer
This trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery for stage III lung cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes.
Jinan, ShandongAges 18–75 - NCT00044122Recruiting
Study of mast cell growth in people with mastocytosis
This study looks at what causes mast cells to grow too much in people with mastocytosis. It may help researchers find better ways to diagnose or treat this condition. You can take part in person or by telehealth.
Bethesda, MarylandAges 1 day–80 years - NCT07405151RecruitingPhase 1/Phase 2
New drug for advanced esophageal cancer after other treatments
This trial tests a new drug called Ifinatamab Deruxtecan for people with advanced esophageal squamous cell carcinoma that has progressed after one or two prior treatments. It aims to see if the drug can shrink tumors or slow the disease.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT07061977RecruitingPhase 3
New cancer drug combo for advanced cervical cancer
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Birmingham, AlabamaAges 18 years+ - NCT06406465RecruitingPhase 2
Belinostat trial for neuroendocrine cancer based on genetics
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
Bethesda, MarylandAges 18–120 - NCT05208307RecruitingPhase 2
Belantamab with pomalidomide and dexamethasone after high-risk myeloma transplant
This Phase 2 study tests a treatment combination (belantamab mafodotin, pomalidomide, and dexamethasone) for high-risk multiple myeloma after an autologous stem cell transplant. It aims to improve disease control in people who have certain genetic features or aggressive disease behavior.
Atlanta, GeorgiaAges 18 years+ - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Mobile, AlabamaAges 18 years+ - NCT07173270Recruiting
Improving oral health in head and neck cancer survivors
This trial aims to improve oral health in people being treated for head and neck cancer. If you are receiving radiation therapy, this study may help manage side effects and keep your mouth healthier.
UppsalaAges 18 years+ - NCT06646237Recruiting
Using a blood test to diagnose TB in pleural fluid
This study tests a new blood test that looks for TB DNA to see if it can help diagnose tuberculosis in people who have fluid around one lung. If the test works, it might make diagnosing TB faster and less invasive.
Hong Kong, Hong KongAges 18 years+ - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Phoenix, ArizonaAges 18 years+ - NCT02471352Recruiting
Share skin samples for dermatology research
This study collects and stores biological samples (biospecimens) from people with skin conditions, people at risk, or healthy volunteers. It helps researchers better understand dermatologic diseases and support future skin research.
Bethesda, MarylandAges 1 day–100 years - NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Denver, ColoradoAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,682 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.